Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma

Abstract

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly evolving with improved knowledge of the biology of disease leading to the incorporation of a variety of antiangiogenic agents and immunotherapies. In this review, we discuss historical, current, and emerging first line treatment options for patients with advanced ccRCC. These include data with single agent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs): sunitinib, pazopanib and cabozantinib as well as the recently reported results for the combination of lenvatinib and everolimus (mTOR inhibitor). We also discuss results of the nivolumab anti-programmed cell death (PD-1)/ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4) combination as well as emerging front-line data with nivolumab and pembrolizumab (anti-PD-1) monotherapy. Finally, we review data supporting recent approvals of TKI and anti-PD-1 or anti-PD-Ligand 1 (PD-L1) combinations (e.g., axitinib/pembrolizumab, axitinib/avelumab and cabozantinib/nivolumab) and initial outcomes of lenvatinib (multi-kinase inhibitor) and pembrolizumab. With many individual and combination treatment options and the lack of head-to-head comparisons, treatment selection will depend on the goals of therapy (endpoints) and the identification and validation of clinical and tumor-based predictive biomarkers that are linked to the desired treatment endpoints.

Keywords

Renal cell carcinoma / nivolumab / ipilimumab / axitinib / pembrolizumab / avelumab / biomarkers

References

[1] Ferlay J,Soerjomataram I.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer2019;144:1941-53

[2] Padala SA,Thandra KC.Epidemiology of Renal Cell Carcinoma.World J Oncol2020;11:79-87 PMCID:PMC7239575

[3] Sorbellini M,Snyder ME.A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.J Urol2005;173:48-51

[4] Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html [Last accessed on 21 May 2021]

[5] Dizman N,Pal SK.Genomic profiling in renal cell carcinoma.Nat Rev Nephrol2020;16:435-51

[6] Ricketts CJ,Fan H.Cancer Genome Atlas Research NetworkThe cancer genome atlas comprehensive molecular characterization of renal cell carcinoma.Cell Rep2018;23:3698

[7] Nickerson ML,Shi Y.Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.Clin Cancer Res2008;14:4726-34 PMCID:PMC2629664

[8] Shen C.The VHL/HIF axis in clear cell renal carcinoma.Semin Cancer Biol2013;23:18-25 PMCID:PMC3663044

[9] Gossage L,Maher ER.VHL, the story of a tumour suppressor gene.Nat Rev Cancer2015;15:55-64

[10] Motzer RJ,Tomczak P.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol2009;27:3584-90 PMCID:PMC3646307

[11] Sternberg CN,Mardiak J.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol2010;28:1061-8

[12] Motzer RJ,Cella D.Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med2013;369:722-31

[13] Choueiri TK,Sanford BL.Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial.J Clin Oncol2017;35:591-7 PMCID:PMC5455807

[14] Iyer G,Milowsky MI.Genome sequencing identifies a basis for everolimus sensitivity.Science2012;338:221 PMCID:PMC3633467

[15] Motzer RJ,McDermott DF.CheckMate 025 investigatorsNivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13 PMCID:PMC5719487

[16] Motzer RJ,McDermott DF.CheckMate 214 InvestigatorsNivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med2018;378:1277-90 PMCID:PMC5972549

[17] Heng DY,Regan MM.External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.Lancet Oncol2013;14:141-8 PMCID:PMC4144042

[18] Motzer RJ,Murphy BA,Mazumdar M.Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.J Clin Oncol2002;20:289-96

[19] Jubb AM,Hanby AM.Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.J Clin Pathol2004;57:504-12 PMCID:PMC1770303

[20] Goel S,Xu L.Normalization of the vasculature for treatment of cancer and other diseases.Physiol Rev2011;91:1071-121 PMCID:PMC3258432

[21] Sennino B.Controlling escape from angiogenesis inhibitors.Nat Rev Cancer2012;12:699-709 PMCID:PMC3969886

[22] Lai Y,Zeng T.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.Cancer Cell Int2018;18:31 PMCID:PMC5838927

[23] Escudier B,Bono P.Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study.J Clin Oncol2014;32:1412-8

[24] Hudes G,Tomczak P.Global ARCC TrialTemsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med2007;356:2271-81

[25] Motzer RJ,Kim TM.Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.J Clin Oncol2014;32:2765-72 PMCID:PMC5569681

[26] Motzer RJ,Boyle S.NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.J Natl Compr Canc Netw2020;18:1160-70

[27] Zhou L,Sun M.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Oncogene2016;35:2687-97 PMCID:PMC4791213

[28] Choueiri TK,Halabi S.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update.Eur J Cancer2018;94:115-25 PMCID:PMC6057479

[29] Motzer R,Rha SY.CLEAR Trial InvestigatorsLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.N Engl J Med2021;384:1289-300

[30] Hutson TE,Al-shukri S.Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.Lancet Oncol2013;14:1287-94

[31] Motzer RJ,Eisen T.Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.J Clin Oncol2013;31:3791-9 PMCID:PMC5569677

[32] Motzer RJ,Tomczak P.Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol2013;14:552-62

[33] Rini BI,Escudier BJ.Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.Lancet Oncol2020;21:95-104

[34] McDermott DF,Signoretti S.The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.Clin Cancer Res2015;21:561-8 PMCID:PMC4315731

[35] Coppin C,Autenrieth M. Immunotherapy for advanced renal cell cancer. Cochrane database of systematic reviews. Chichester: John Wiley & Sons, Ltd; 1996.

[36] Blankenstein T,Gilboa E.The determinants of tumour immunogenicity.Nat Rev Cancer2012;12:307-13 PMCID:PMC3552609

[37] Kopecky O,Vroblová V.Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.Acta Medica (Hradec Kralove)2007;50:207

[38] Komohara Y,Ohnishi K.Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.Cancer Sci2011;102:1424-31

[39] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[40] Walker LS.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.Nat Rev Immunol2011;11:852-63

[41] Dong Y,Zhang X.PD-1 and its ligands are important immune checkpoints in cancer.Oncotarget2017;8:2171 PMCID:PMC5356790

[42] Hammers HJ,Infante JR.Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study.J Clin Oncol2017;35:3851-8 PMCID:PMC7587408

[43] Motzer RJ,McDermott DF.Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.J Immunother Cancer2020;8:e000891 PMCID:PMC7359377

[44] Tannir NM,Escudier B.Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).J Clin Oncol2020;38:6_suppl, 609

[45] Tannir NM,Choueiri TK.Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.Clin Cancer Res2021;27:78-86

[46] Tykodi SS,Lee JL,Malik J et al.First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated results for KEYNOTE-427 cohort A.J Clin Oncol2019;37:15_suppl, 4570

[47] Atkins MB,Haas NB.Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).J Clin Oncol2020;38(15_suppl):5006

[48] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03873402 (2021) [Last accessed on 21 May 2021]

[49] Guislain A,Kaiser A.Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.Cancer Immunol Immunother2015;64:1241-50

[50] Kwilas AR,Donahue RN,Hodge JW.Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.J Transl Med2014;12:294 PMCID:PMC4236498

[51] Li YL,Ren XB.Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?.Cancer Biol Med2016;13:206-14 PMCID:PMC4944543

[52] Kwilas AR,Tsang KY.Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.Cancer Cell Microenviron2015;2:e677 PMCID:PMC4440700

[53] Zhang Q,Xu J.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.J Immunol Res2017;2017:6915912 PMCID:PMC5750507

[54] Bao Y,Liu B.A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis.Oncogene2019;38:881-95 PMCID:PMC6367212

[55] Liu XD,Zhou L.Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.Cancer Immunol Res2015;3:1017-29 PMCID:PMC4561186

[56] Hipp MM,Walter S.Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.Blood2008;111:5610-20

[57] Amin A,Ernstoff MS.Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.J Immunother Cancer2018;6:109 PMCID:PMC6196426

[58] Rini BI,Atkins MB.Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.Lancet2019;393:2404-15

[59] Rini BI,Stus V.KEYNOTE-426 InvestigatorsPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2019;380:1116-27

[60] Powles T,Soulières D,Stus V et al.Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial.Lancet Oncol2020;21:1563-73

[61] Motzer RJ,Haanen J.Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med2019;380:1103-15 PMCID:PMC6716603

[62] Choueiri TK,Rini BI.Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.Ann Oncol2020;31:1030-9

[63] Choueiri TK,Burotto M.CheckMate 9ER InvestigatorsNivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2021;384:829-41

[64] Regan MM,Powles T,Mantia C et al.Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma.Ann Oncol2019;30:v393-4

[65] Regan M,Mantia C,Werner L et al.713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214.Ann Oncol2020;31:S561

[66] Cella D,Escudier B.Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.Lancet Oncol2019;20:297-310 PMCID:PMC6701190

[67] Leite KR,Junior JP.PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.Diagn Pathol2015;10:189 PMCID:PMC4608287

[68] Iacovelli R,Verri E.Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.Target Oncol2016;11:143-8

[69] Motzer RJ,Hamidi H.Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.Cancer Cell2020;38:803-17.e4

[70] Kapur P,Rajaram S.What morphology can teach us about renal cell carcinoma clonal evolution.Kidney Cancer J2020;18:68-75

[71] Gu YF,Christie A.Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade.Cancer Discov2017;7:900-17 PMCID:PMC5540776

[72] Brugarolas J,Christie A.The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm.Cancer Cell2020;38:771-3

[73] Flanigan RC,Blumenstein BA.Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.N Engl J Med2001;345:1655-9

[74] Mickisch G,van Poppel H,Sylvester R.Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.Lancet2001;358:966-70

[75] Méjean A,Thezenas S.Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.N Engl J Med2018;379:417-27

[76] Bex A,Jewett M.Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.JAMA Oncol2019;5:164-70 PMCID:PMC6439568

[77] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03977571 (2021) [Last accessed on 21 May 2021]

[78] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04090710 (2021) [Last accessed on 21 May 2021]

[79] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04322955 (2021) [Last accessed on 21 May 2021]

[80] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04510597 (2021) [Last accessed on 21 May 2021]

[81] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03937219 (2021) [Last accessed on 21 May 2021]

[82] US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03793166 (2021) [Last accessed on 21 May 2021]